Skip to content
Home/Companies/Biotech/Cytely

Cytely

Biotech·Sweden·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Cytely?

Cytely is a Swedish Biotech company, currently owned by Ugly Duckling Ventures since 2025.

Hand-verified · updated 2026-08-19

Open JSON · CC-BY
Ugly Duckling Ventures
Investor
Ugly Duckling Ventures
Fund II · 2023 · VC

Key facts

HQSweden
SectorBiotech
StatusActive

More from Fund II

Other portfolio companies in the same fund.

FNS
Active
FintechDenmark· 2026
Palette
Active
AI/MLDenmark· 2026
Velatir
Active
AI/MLDenmark· 2026
Clock&Cloud
Active
Data & AnalyticsFinland· 2025
P-Secure
Active
HR TechDenmark· 2025
Pentimenti
Active
SaaSDenmark· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Cytely?

Cytely is currently owned by Ugly Duckling Ventures, through Fund II, since 2025.

When did Ugly Duckling Ventures acquire Cytely?

Ugly Duckling Ventures acquired Cytely in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue